Vorinostat

drugbox
IUPAC_name = "N"-hydroxy-"N"'-phenyl-octanediamide

---

CAS_number = 149647-78-9
ATC_prefix =
ATC_suffix =
PubChem = 5311
DrugBank = DB02546
C = 14 | H = 20 | N = 2 | O = 3
molecular_weight = 264.32 g/mol
bioavailability =
protein_bound = 71%
metabolism = Hepatic glucuronidation and oxidation
CYP system not involved
elimination_half-life = 2 hours
excretion = Renal (negligible)
pregnancy_AU =
pregnancy_US = D
pregnancy_category =
licence_US = Vorinostat
legal_AU =
legal_CA =
legal_UK =
legal_US = Rx-only
legal_status =
routes_of_administration = Oral

Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA) is a member of a larger class of compounds that inhibit histone deacetylases (HDAC). Histone deacetylase inhibitors (HDI) have a broad spectrum of epigenetic activities. SAHA is marketed under the name "Vorinostat", brand name "Zolinza", for the treatment of cutaneous T cell lymphoma (CTCL) when the disease persists, gets worse, or comes back during or after treatment with other medicines. It has also been used to treat Sézary's disease, another type of lymphoma closely related to CTCL.cite web | last = Cuneo A | first = Castoldi | title = Mycosis fungoidses/Sezary's syndrome | url=http://atlasgeneticsoncology.org/Anomalies/MycosFungID2039.html | accessdate = 2008-02-15 ]

A recent study suggested that vorinostat also possesses some activity against recurrent glioblastoma multiforme, resulting in a median overall survival of 5.7 months (compared to 4 - 4.4 months in earlier studies). Further brain tumor trials are planned in which vorinostat will be combined with other drugs.

Zolinza was approved by the U.S. Food and Drug Administration (FDA) for the treatment of CTCL on October 6, 2006, and it is manufactured by Patheon, Inc., in Mississauga, Ontario, Canada, for Merck & Co., Inc., White House Station, New Jersey.

References

* cite press release
title = ZOLINZA, Merck's Investigational Medicine for Advanced Cutaneous T-Cell Lymphoma (CTCL), To Receive Priority Review from U.S. Food and Drug Administration
publisher = Merck & Co.
date = June 7, 2006
url = http://www.merck.com/newsroom/press_releases/research_and_development/2006_0607.html
accessdate = 2006-10-06

*cite press release
title = FDA Approves New Drug for Skin Cancer, Zolinza
publisher = Food and Drug Administration
date = October 6, 2006
url = http://www.fda.gov/bbs/topics/NEWS/2006/NEW01484.html
accessdate = 2006-10-06

*cite press release
title = Vorinostat shows anti-cancer activity in recurrent gliomas
publisher = Mayo Clinic
date = June 3, 2007
url = http://www.eurekalert.org/pub_releases/2007-06/mc-vsa053007.php
accessdate = 2007-06-03

ee also

*Histone deacetylase inhibitor
*Trichostatin A